NEW ORLEANS — For people with type 2 diabetes (T2D) inadequately controlled on submaximal dulaglutide (Trulicity) doses, switching to tirzepatide (Mounjaro) produces significantly greater A1c and weight lowering than does escalating dulaglutide treatment. “Often, when we are with a patient who is not meeting treatment goals...
TheFeel, námestí Smirických, Kostelec n. C. Lesy 28163, Czechia
+31613054419
info@thefeel.org
Copyright © 2023 news.thefeel.org. All Rights Reserved
